Development of new antituberculosis drugs from natural products†
- 2 January 2017
- journal article
- review article
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 81 (1) , 32-37
Abstract
(2017). Development of new antituberculosis drugs from natural products. Bioscience, Biotechnology, and Biochemistry: Vol. 81, No. 1, pp. 32-37.Keywords
This publication has 24 references indexed in Scilit:
- Novel semisynthetic antibiotics from caprazamycins A–G: caprazene derivatives and their antibacterial activityThe Journal of Antibiotics, 2013
- Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in vitro and During InfectionPLOS Pathogens, 2012
- In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine ModelAntimicrobial Agents and Chemotherapy, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Gatifloxacin in combination with rifampicin in a murine tuberculosis modelJournal of Antimicrobial Chemotherapy, 2007
- Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB DrugsAntimicrobial Agents and Chemotherapy, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Cyclomarins A−C, New Antiinflammatory Cyclic Peptides Produced by a Marine Bacterium (Streptomyces sp.)Journal of the American Chemical Society, 1999